Dr. Lewis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
24075 Commerce Park
Beachwood, OH 44122Phone+1 216-831-5704Fax+1 216-831-1959
Summary
- Dr. Lewis received his BS degree magna cum laude from Xavier University and his MD degree from the University of Cincinnati College of Medicine. His ophthalmology residency was at the University of Cincinnati Medical Center and his vitreoretinal surgery fellowship was at the University of Chicago.
Dr. Lewis's principal areas of interest are macular surgery, retinal detachment surgery, age-related macular degeneration, diabetic retinopathy, and retinal lasers.
Education & Training
University of ChicagoFellowship, Surgical Retina and Vitreous, 2013 - 2015
University of Cincinnati Medical Center/College of MedicineResidency, Ophthalmology, 2010 - 2013
TriHealth (Good Samaritan Hospital)Internship, Internal Medicine, 2009 - 2010
University of Cincinnati College of MedicineClass of 2009
Xavier UniversityB.S., Biology, Magna Cum Laude, 2001 - 2005
Certifications & Licensure
OH State Medical License 2015 - 2026
PA State Medical License 2019 - 2024
IL State Medical License 2013 - 2017- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Joseph Peters Scholarship Award 2003
- Schawe Scholarship 2001
Publications & Presentations
PubMed
- 7 citationsRetinal Toxicity Associated With MEK Inhibitor Use for Metastatic Cancer: A Rising Trend in Ophthalmology.Daniel P. Nolan, Shawn A. Lewis, Seenu M. Hariprasad
Ophthalmic Surgery, Lasers & Imaging Retina. 2016-05-01 - 17 citationsAnalysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis.Douglas A. Cionni, Shawn A. Lewis, Michael R. Petersen, Robert E. Foster, Christopher D. Riemann
Ophthalmology. 2012-02-01 - 9 citationsSwitching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular d...Joseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou
International Journal of Retina and Vitreous. 2023-02-01
Journal Articles
- Acute exudative polymorphous paraneoplastic vitelliform maculopathy in a patient with carcinoma, not melanomaGrunwald L, Kligman B, Shields C, Arch Ophthalmol, 1/1/2011
- Chemical modulation of the chaperone function of human 5-A-crystallinBiswas A, Lewis S, Wang B, Miyagi M. Santoshkumar P, Gangadhariah MH, Nagaraj RH, J Biochem, 1/1/2008
- Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injuryGopez J, Yue H, Vasudevan R, Malik A. Fogelsanger L, Lewis S, Panikashvili D, Shohami E, Jansen S, Narayan R, Strauss K, Neurosurgery, 1/1/2005
Press Mentions
Coronavirus: London, Ont., Councillors Call for Discussion on Mandatory Masks PolicyJuly 14th, 2020- Retinal Toxicity Associated with MEK Inhibitor Use for Metastatic Cancer: A Rising Trend in OphthalmologyMay 18th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
